News & Perspective

Oct 18, 2011

Oct 18, 2011

Anthrax countermeasures better than in 2001, but work remains

(CIDRAP News) – If someone tried to kill Americans with Bacillus anthracis spores today, the nation would have a better medical tool chest for treating the sick and those potentially exposed than it had 10 years ago, when the anthrax letter attacks killed five people, but anthrax defenses are still a work in progress.

Aug 12, 2008

Aug 12, 2008

HHS evaluates proposals for new anthrax vaccine

(CIDRAP News) – Two Maryland pharmaceutical companies recently announced that they have submitted proposals to produce and deliver at least 25 million doses of a next-generation anthrax vaccine to the nation's Strategic National Stockpile.

Apr 08, 2008

Apr 08, 2008

DoD funds development of anthrax vaccine patch

(CIDRAP News) – Iomai Corp., a biotechnology company that specializes in needle-free vaccines, announced today that it will receive a grant from the US Department of Defense (DoD) to fund preclinical development of a patch-based anthrax vaccine.

The 1-year grant to Iomai, based in Gaithersburg, Md., will be in the form of a $943,856 cost reimbursement from the US Army Medical Research and Material Command, according to a press release from Iomai.

Jan 23, 2008

Jan 23, 2008

GAO cites barriers to antiviral, vaccine roles in pandemic

(CIDRAP News) – Antiviral medications and vaccines are two tools that many government and health officials hope will stall the spread of an influenza pandemic, but each strategy has daunting challenges, according to a new report from Congress's Government Accountability Office (GAO).

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»